{"id":6661,"date":"2024-11-21T14:51:10","date_gmt":"2024-11-21T13:51:10","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6661"},"modified":"2025-04-28T21:50:44","modified_gmt":"2025-04-28T19:50:44","slug":"tislelizumab-plus-chemotherapy-versus-chemotherapy-alone-as-first-line-treatment-for-advanced-squamous-non-small-cell-lung-cancer-final-analysis-of-the-randomized-phase-iii-rationale-307-trial","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/tislelizumab-plus-chemotherapy-versus-chemotherapy-alone-as-first-line-treatment-for-advanced-squamous-non-small-cell-lung-cancer-final-analysis-of-the-randomized-phase-iii-rationale-307-trial\/","title":{"rendered":"Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6661","publication","type-publication","status-publish","hentry","disease_state-non-small-cell-lung-cancer","molecule-tislelizumab"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6661"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}